Company

MGC Pharmaceuticals Limited

Headquarters: West Perth, WA, Australia

CEO: Mr. Roby Reuven Zomer

ASX: MXC

Market Cap

A$17.5 Million

AUD as of Jan. 1, 2024

US$11.9 Million

Market Cap History

MGC Pharmaceuticals Limited market capitalization over time

Evolution of MGC Pharmaceuticals Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of MGC Pharmaceuticals Limited

Detailed Description

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

MGC Pharmaceuticals Limited has the following listings and related stock indices.


Stock: ASX: MXC wb_incandescent

Stock: OTC: MGCLF wb_incandescent

Details

Headquarters:

1202 Hay Street

West Perth, WA 6005

Australia

Phone: 61 8 6382 3390